<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Füllhase C</dc:creator>
  <dc:creator>Schneider MP</dc:creator>
  <dc:date>2016</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (&gt;30-40ml). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI / alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/277258</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ucl.2016.04.003</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27476125</dc:relation>
  <dc:source>The Urologic clinics of North America. - 2016</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">5-Alpha-reductase inhibitors</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Combination drug therapy</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Dutasteride</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Finasteride</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Lower urinary tract symptoms</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Prostatic hyperplasia</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">5-alpha Reductase Inhibitors</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Adrenergic alpha-Antagonists</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Drug Therapy, Combination</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Prostatic Hyperplasia</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Testosterone</dc:subject>
  <dc:title xmlns:ns14="xml" ns14:lang="en">5-Alpha-Reductase Inhibitors and Combination Therapy.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>